Surrogate endpoints for clinical trials in non-alcoholic steatohepatitis
Lancet Gastroenterol Hepatol
.
2017 Aug;2(8):549-550.
doi: 10.1016/S2468-1253(17)30184-X.
Authors
Emmanuel A Tsochatzis
1
,
Elena Buzzetti
2
,
Massimo Pinzani
2
Affiliations
1
UCL Institute for Liver and Digestive Health, Royal Free Hospital and UCL, London NW3 2QG, UK. Electronic address: e.tsochatzis@ucl.ac.uk.
2
UCL Institute for Liver and Digestive Health, Royal Free Hospital and UCL, London NW3 2QG, UK.
PMID:
28691682
DOI:
10.1016/S2468-1253(17)30184-X
No abstract available
Publication types
Letter
Comment
MeSH terms
Biomarkers*
Humans
Liver
Non-alcoholic Fatty Liver Disease*
Substances
Biomarkers